Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Sunday. The brokerage set a “hold” rating on the stock.

ONCT has been the topic of a number of other reports. Northland Capmk lowered Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Northland Securities reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Price Performance

Shares of ONCT opened at $0.53 on Friday. Oncternal Therapeutics has a one year low of $0.53 and a one year high of $13.14. The company has a market cap of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The stock has a 50-day moving average of $0.98 and a 200-day moving average of $3.40.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.